osimertinib + bevacizumab

Osimertinib + bevacizumab is an investigational drug combination consisting of two agents used in oncology. Osimertinib is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that selectively inhibits both EGFR-sensitizing and EGFR T790M resistance mutations. Bevacizumab is a recombinant humanized monoclonal antibody targeting vascular endothelial growth factor A (VEGF-A), thereby inhibiting angiogenesis required for tumor growth. The combination aims to provide synergistic antitumor effects by simultaneously blocking tumor cell proliferation via EGFR inhibition and suppressing tumor vascularization through VEGF inhibition. This regimen is being studied primarily as first-line therapy for patients with metastatic non-small cell lung cancer (NSCLC) harboring activating EGFR mutations[1][3][5][7].

Other names

osimertinib plus bevacizumabosimertinib and bevacizumab combination